Verve Therapeutics (NASDAQ: VERVE) is on the watchlists of many investors today after a 25% surge in the last few days.
Verve Therapeutics is on the up and this article explains why. In addition, we discuss whether or not now is a good time to buy shares in the company.
To kick things off, let’s see our analysts’ top picks of the best places to buy VERVE stock online.
Where to buy Verve Therapeutics shares right now
If you want to invest in VERVE, sign up to a reliable online stockbroker and fund your account. You can then invest in VERVE shares, along with many other publicly traded companies, commodities, cryptocurrencies, and even the forex market.
Here are our two top picks thanks to their low fees, quality service and general ease of use:
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
What is Verve Therapeutics?
Verve Therapeutics is a genetic medicines company that is aiming to pioneer a new approach to the care of cardiovascular disease. The long-term goal of the company is to transform treatment from chronic management to single-course gene editing medicines.
This sort of innovation captured the attention of many investors – both institutional and retail – when it launched its upsized $267 million IPO a few days ago.
Should I buy VERVE stock today?
If you want to invest in a high-risk company with the potential for meaningful rewards, Verve could be a great option for you. However, since the company has only just gone public, expect there to be plenty of volatility along the road to growth.
Make sure you conduct your own extensive due diligence and recognise that pharmaceutical stocks carry an increased risk because of the need to progress treatments through extensive, rigorous testing processes before achieving commercialisation.